PetMed Express, Inc. (NASDAQ:PETS) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.

Several other research firms have also recently issued reports on PETS. Credit Suisse Group restated an “underperform” rating and set a $19.00 price objective on shares of PetMed Express in a research report on Monday. Noble Financial reaffirmed a “hold” rating on shares of PetMed Express in a research note on Wednesday, July 26th. Northcoast Research upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 target price on the stock in a report on Monday, July 24th. Zacks Investment Research lowered shares of PetMed Express from a “strong-buy” rating to a “hold” rating in a report on Monday, September 25th. Finally, Sidoti upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. PetMed Express has an average rating of “Hold” and a consensus target price of $39.60.

Shares of PetMed Express (NASDAQ:PETS) traded up 3.14% during trading on Monday, reaching $34.19. 528,367 shares of the company traded hands. PetMed Express has a 52 week low of $18.90 and a 52 week high of $50.90. The stock has a market capitalization of $704.45 million, a PE ratio of 26.30 and a beta of 1.03. The firm has a 50 day moving average of $37.60 and a 200 day moving average of $34.59.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings results on Monday, July 24th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.38 by $0.07. PetMed Express had a return on equity of 28.67% and a net margin of 10.34%. The business had revenue of $79.66 million for the quarter, compared to analyst estimates of $77.32 million. During the same quarter in the previous year, the firm earned $0.32 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. On average, equities analysts predict that PetMed Express will post $1.44 EPS for the current year.

WARNING: “PetMed Express, Inc. (PETS) Downgraded by ValuEngine” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/petmed-express-inc-pets-downgraded-by-valuengine/1604081.html.

In related news, CFO Bruce S. Rosenbloom sold 6,833 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $50.18, for a total transaction of $342,879.94. Following the completion of the sale, the chief financial officer now directly owns 18,534 shares of the company’s stock, valued at approximately $930,036.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronald J. Korn sold 5,000 shares of the business’s stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $48.18, for a total transaction of $240,900.00. Following the completion of the sale, the director now owns 67,333 shares in the company, valued at $3,244,103.94. The disclosure for this sale can be found here. In the last ninety days, insiders sold 19,333 shares of company stock worth $949,730. Corporate insiders own 4.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its stake in PetMed Express by 11.8% during the first quarter. Renaissance Technologies LLC now owns 1,786,315 shares of the company’s stock worth $35,976,000 after buying an additional 188,615 shares during the period. Vanguard Group Inc. increased its position in shares of PetMed Express by 21.0% during the second quarter. Vanguard Group Inc. now owns 1,300,725 shares of the company’s stock valued at $52,810,000 after acquiring an additional 225,474 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of PetMed Express by 8.3% during the second quarter. Dimensional Fund Advisors LP now owns 860,601 shares of the company’s stock valued at $34,940,000 after acquiring an additional 65,932 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of PetMed Express during the second quarter valued at about $18,691,000. Finally, Uniplan Investment Counsel Inc. increased its position in shares of PetMed Express by 5.4% during the first quarter. Uniplan Investment Counsel Inc. now owns 441,393 shares of the company’s stock valued at $8,889,000 after acquiring an additional 22,443 shares during the last quarter. 78.91% of the stock is currently owned by institutional investors.

PetMed Express Company Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Analyst Recommendations for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.